Patents by Inventor Hongzhi Miao

Hongzhi Miao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASH1L inhibitors and methods of treatment therewith
    Patent number: 11833210
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: December 5, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L degraders and methods of treatment therewith
    Patent number: 11786602
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: October 17, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • ASH1L degraders and methods of treatment therewith
    Patent number: 11633490
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: April 25, 2023
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20220288217
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Application
    Filed: October 18, 2021
    Publication date: September 15, 2022
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT
    Publication number: 20220072142
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Application
    Filed: September 7, 2021
    Publication date: March 10, 2022
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • ASH1L inhibitors and methods of treatment therewith
    Patent number: 11147885
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: October 19, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L degraders and methods of treatment therewith
    Patent number: 11110177
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 7, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20200246474
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L inhibitors and methods of treatment therewith
    Patent number: 10632209
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: April 28, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20190144442
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20190142961
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • Thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: 10246464
    Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: April 2, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170247391
    Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
    Type: Application
    Filed: September 8, 2015
    Publication date: August 31, 2017
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: RE49687
    Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: October 10, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu